Quality and utility of [


Journal

Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 02 02 2021
accepted: 11 05 2021
pubmed: 24 5 2021
medline: 15 12 2021
entrez: 23 5 2021
Statut: ppublish

Résumé

Impaired cardiac adrenergic activity has been demonstrated in heart failure (HF) and in diabetes mellitus (DM). [ Consecutive patients receiving an ICD on the basis of contemporary guidelines were prospectively included. Planar MIBG studies were followed by SPECT. The essential analysis was based on visual assessment of the quality of SPECT images ("high", "low" or "unacceptable"). The variables used in the further analysis were late summed defect score for SPECT images and heart-to-mediastinum rate for planar images. MIBG images were assessed independently by two experienced readers. Fifty postinfarction nondiabetic HF subjects were enrolled. In 13 patients (26%), the assessment of SPECT studies was impossible. In addition, in 13 of 37 patients who underwent semiquantitative SPECT evaluation, the assessment was equivocal. Altogether, in 26/50 patients (52%, 95% confidence interval 38-65%), the quality of SPECT images was unacceptable or low and was limited by low MIBG cardiac uptake and by comparatively high, interfering MIBG uptake in the neighboring structures (primarily, in the lungs). The utility of MIBG SPECT imaging, at least with conventional imaging protocols, in the qualification of postinfarction HF patients for ICD, is limited. In approximately half of the postinfarction HF patients, SPECT assessment of cardiac innervation can be impossible or equivocal, even without additional damage from diabetic cardiac neuropathy. The criteria predisposing the patient to good-quality MIBG SPECT are: high values of LVEF from the range characterizing the patients qualified to ICD (i.e., close to 35%) and left lung uptake intensity in planar images comparable to or lower than heart uptake.

Identifiants

pubmed: 34023989
doi: 10.1007/s12149-021-01628-1
pii: 10.1007/s12149-021-01628-1
pmc: PMC8285320
doi:

Substances chimiques

3-Iodobenzylguanidine 35MRW7B4AD

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

916-926

Informations de copyright

© 2021. The Author(s).

Références

J Nucl Cardiol. 2006 Jan-Feb;13(1):34-42
pubmed: 16464715
J Nucl Cardiol. 2017 Apr;24(2):377-391
pubmed: 26791866
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
J Nucl Cardiol. 2014 Oct;21(5):913-20
pubmed: 24858625
Nucl Med Commun. 1997 Aug;18(8):761-70
pubmed: 9293507
Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1802-12
pubmed: 20577740
J Nucl Cardiol. 2019 Feb;26(1):109-117
pubmed: 28500540
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
J Nucl Med. 1981 Feb;22(2):129-32
pubmed: 7463156
J Nucl Med. 2015 Jun;56 Suppl 4:25S-30S
pubmed: 26033900
Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1322-8
pubmed: 19259662
J Am Coll Cardiol. 2010 Jun 15;55(24):2769-77
pubmed: 20538172
Rev Esp Med Nucl Imagen Mol. 2016 Mar-Apr;35(2):74-80
pubmed: 26514320
J Am Coll Cardiol. 2010 May 18;55(20):2212-21
pubmed: 20188504
Eur J Nucl Med Mol Imaging. 2012 Oct;39(10):1599-608
pubmed: 22790878
Semin Nucl Med. 2014 Jul;44(4):294-313
pubmed: 24948152
J Nucl Cardiol. 2016 Jun;23(3):436-41
pubmed: 25802176
Circulation. 1987 Apr;75(4):877-87
pubmed: 3829345
J Nucl Med. 1998 Feb;39(2):334-8
pubmed: 9476946
Diabetes Care. 2013 Aug;36(8):2395-401
pubmed: 23530014
Diabetes. 1992 Sep;41(9):1069-75
pubmed: 1499860
J Gastroenterol Hepatol. 2020 Dec;35(12):2151-2157
pubmed: 32410288
J Nucl Cardiol. 2016 Jun;23(3):425-35
pubmed: 25788403
Acta Oncol. 2011 Aug;50(6):851-8
pubmed: 21767184
Am Heart J. 1993 Aug;126(2):390-8
pubmed: 8338010
Circ Arrhythm Electrophysiol. 2015 Jun;8(3):583-91
pubmed: 25713216
Circ Res. 2013 Aug 30;113(6):739-53
pubmed: 23989716
Circulation. 2013 Oct 15;128(16):e240-327
pubmed: 23741058
J Am Coll Cardiol. 1995 Mar 1;25(3):610-8
pubmed: 7860904
Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1549-57
pubmed: 23740373
J Nucl Cardiol. 2019 Oct;26(5):1555-1565
pubmed: 29344924
Int J Cardiol. 2013 Sep 30;168(2):1556-8
pubmed: 23333364
J Nucl Cardiol. 2010 Dec;17(6):1107-15
pubmed: 20857351
Circulation. 1988 Oct;78(4):1008-19
pubmed: 3168182
Circ Cardiovasc Imaging. 2008 Sep;1(2):131-40
pubmed: 19808530
J Nucl Cardiol. 2012 Aug;19(4):752-62
pubmed: 22669736
J Nucl Med. 1996 Dec;37(12):1985-90
pubmed: 8970519
Am Heart J. 1990 Jun;119(6):1329-37
pubmed: 2353619
J Nucl Cardiol. 2019 Aug;26(4):1188-1196
pubmed: 29594915
Circ Cardiovasc Imaging. 2011 Mar;4(2):87-93
pubmed: 21193691
J Nucl Cardiol. 2012 Feb;19(1):92-9
pubmed: 22147616

Auteurs

Anna Teresińska (A)

National Institute of Cardiology, Alpejska 42, 04-628, Warsaw, Poland. ateresinska@ikard.pl.

Olgierd Woźniak (O)

National Institute of Cardiology, Alpejska 42, 04-628, Warsaw, Poland.

Aleksander Maciąg (A)

National Institute of Cardiology, Alpejska 42, 04-628, Warsaw, Poland.

Jacek Wnuk (J)

National Institute of Cardiology, Alpejska 42, 04-628, Warsaw, Poland.

Jarosław Jezierski (J)

National Institute of Cardiology, Alpejska 42, 04-628, Warsaw, Poland.

Aneta Fronczak (A)

National Institute of Cardiology, Alpejska 42, 04-628, Warsaw, Poland.

Elżbieta Katarzyna Biernacka (EK)

National Institute of Cardiology, Alpejska 42, 04-628, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH